Skip to main content
2023 BMES Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

    Tissue Engineering

    (L-461) An Engineered Gut-Liver Platform Utilizing Primary Human Hepatocytes and Intestinal Epithelial Cells

    Friday, October 13, 2023
    9:30 AM – 10:30 AM PDT
    Location: Exhibit Hall - Row L - Poster # 461

      Presenting Author(s)

    • DS

      Dinithi Samarasekera

      PhD Student
      University of Illinois Chicago
      Chicago, Illinois, United States

      • Primary Investigator(s)

    • Salman R. Khetani (he/him/his)

      Professor and Director of Graduate Studies
      University of Illinois Chicago
      Chicago, Illinois, United States

    Orally administered drugs undergo intestinal metabolism and selective absorption before transport to the liver for further metabolism. Such intestinal-liver crosstalk can significantly impact drug bioavailability and efficacy by the time it reaches a patient’s systemic circulation. Unfortunately, most in vitro gut-liver models fail to recapitulate in vivo metabolic functionality, such as cytochrome P450 (CYP) activity, as they rely on immortalized tumor cell lines and/or de-differentiated primary cell monolayers. Despite considerable progress in developing human intestine and liver models using primary cells, little has been done in engineering integrated primary human gut-liver models. We have previously developed a micropatterned co-culture (MPCC) model of the human liver containing primary human hepatocytes (PHHs) and supportive fibroblasts that displays stable hepatic functions for several weeks in vitro. Here, we utilize MPCCs with primary intestinal epithelial cells to develop a modular and human gut-liver model for drug screening, disease modeling, and to investigate organ-organ crosstalk